Key Drivers
- High Margins
- Weak Liquidity
- Cash Flow Risk
AIAI Summary
PM is increasingly a regulated smoke-free platform rather than a legacy cigarette cash cow, and the investment hinges on whether FDA-backed ZYN/IQOS growth can lift smoke-free mix fast enough to offset combustible decline, justify the premium valuation, and overcome a weak balance sheet and lumpy cash flow.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Margins
- •Weak Liquidity
- •Cash Flow Risk
Philip Morris is highly profitable and cash-generative with strong annual margins and FCF, but negative equity, tight liquidity, and a weak latest quarter make leverage and near-term cash conversion the main risks.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Support holding
- •Breakout needed
PM looks constructive over the last month, holding $177-$178 as support and hovering near resistance at $182.8-$182.9, with a breakout needed to extend gains.
Sharp swing from the 2026-06-16 peak to the 2026-06-22 low shows notable short-term volatility
Sentiment & News
Key News Insights:
- •Smoke-free growth
- •FDA risk claim
- •Dividend support
PMI is strengthening its smoke-free growth story, with IQOS/ZYN driving sales, a key FDA modified-risk win for ZYN, and steady shareholder returns offsetting ongoing cigarette declines.
The FDA ruling and continued smoke-free momentum should support PMI's growth narrative and investor sentiment despite pressure in combustible cigarettes
Similar Companies in Consumer Defensive
Other companies in the same sector with AI ratings